Shao-Qiong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shao-Qiong Chen has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Chang-Ming Huang
Fujian Medical University Union Hospital
14 shared publications - Chao-Hui Zheng
Fujian Medical University Union Hospital
14 shared publications - Cheng Yan
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
14 shared publications - Chuan Feng
Department of Gastric Surgery, Fujian Medical University Union Hospital, Fuzhou, China
14 shared publications - Guang-Tan Lin
Union Hospital 2 Fuzhou, Fujian
14 shared publications - Jian-Wei Xie
Fujian Medical University Union Hospital
14 shared publications
Latest Publications
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S3 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Supplementary Table S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
The therapeutic resistances of MDA tumors were abrogated by β-catenin signaling blockade.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
The therapeutic resistances of MDA tumors were abrogated by β-catenin signaling blockade.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
A single-cell transcriptome atlas dissecting heterogeneity of APTc and MDA tumor.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
A single-cell transcriptome atlas dissecting heterogeneity of APTc and MDA tumor.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Data from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Immune checkpoint blockade (ICB) therapies have achieved significant breakthroughs in cancer treatment over the past decade. However, ICB is largely ineffective in desert-type gastric cancer due to intrinsic tumor heterogeneity and a highly immunosuppressive tumor microenvironment (TME). Transforming tumors from an immunosuppressive state to an immunostimulatory state is a potential approach to enhance ICB response. In this study, we developed a chromosomal instability–subtype gastric cancer mouse model with an immunoactive TME and a stem cell–originated mouse-derived allograft model with an immunosuppressed TME to investigate mechanisms regulating the tumor immunophenotype and uncover therapeutic strategies to remodel the TME. Blocking β-catenin signaling attenuated the immunochemotherapeutic resistance of mouse-derived allograft tumors. The tyrosine kinase inhibitor apatinib reprogrammed the TME by increasing CD8+ T-cell and IGHA+ plasma cell infiltration and decreasing M2 macrophages, but apatinib also induced PD-L1 and CD80 expression in both human and mouse desert–type tumors. Oxaliplatin decreased the apatinib-induced expression of immune checkpoints and enhanced the antitumor efficacy of immunotherapy. A prospective clinical trial (NCT04195828) demonstrated that a neoadjuvant regimen of apatinib plus ICB and chemotherapy was effective in patients with desert-type gastric cancer. Collectively, these findings identify potential drug targets for immune desert–type gastric cancer driven by β-catenin signaling.Significance: Apatinib combined with oxaliplatin reprograms the tumor immune microenvironment in desert-type gastric cancer, enhancing the efficacy of immune checkpoint blockade and paving the way for optimized combination immunotherapeutic strategies.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Immune checkpoint blockade (ICB) therapies have achieved significant breakthroughs in cancer treatment over the past decade. However, ICB is largely ineffective in desert-type gastric cancer due to intrinsic tumor heterogeneity and a highly immunosuppressive tumor microenvironment (TME). Transforming tumors from an immunosuppressive state to an immunostimulatory state is a potential approach to enhance ICB response. In this study, we developed a chromosomal instability–subtype gastric cancer mouse model with an immunoactive TME and a stem cell–originated mouse-derived allograft model with an immunosuppressed TME to investigate mechanisms regulating the tumor immunophenotype and uncover therapeutic strategies to remodel the TME. Blocking β-catenin signaling attenuated the immunochemotherapeutic resistance of mouse-derived allograft tumors. The tyrosine kinase inhibitor apatinib reprogrammed the TME by increasing CD8+ T-cell and IGHA+ plasma cell infiltration and decreasing M2 macrophages, but apatinib also induced PD-L1 and CD80 expression in both human and mouse desert–type tumors. Oxaliplatin decreased the apatinib-induced expression of immune checkpoints and enhanced the antitumor efficacy of immunotherapy. A prospective clinical trial (NCT04195828) demonstrated that a neoadjuvant regimen of apatinib plus ICB and chemotherapy was effective in patients with desert-type gastric cancer. Collectively, these findings identify potential drug targets for immune desert–type gastric cancer driven by β-catenin signaling.Significance: Apatinib combined with oxaliplatin reprograms the tumor immune microenvironment in desert-type gastric cancer, enhancing the efficacy of immune checkpoint blockade and paving the way for optimized combination immunotherapeutic strategies.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Characteristics of 12 patients received neoadjuvant therapy
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Characteristics of 12 patients received neoadjuvant therapy
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Characteristics of 66 patients with gastric cancer in tissue microarray cohort
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Characteristics of 66 patients with gastric cancer in tissue microarray cohort
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Apatinib promotes CD8+ T lymphocyte infiltration and reshapes tumor microenvironment in desert-type GC.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Apatinib promotes CD8+ T lymphocyte infiltration and reshapes tumor microenvironment in desert-type GC.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Neoadjuvant regimen of apatinib plus camrelizumab and chemotherapy is effective for patients with desert-type GC.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
Neoadjuvant regimen of apatinib plus camrelizumab and chemotherapy is effective for patients with desert-type GC.
- Open Access
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
A transgenic mouse model and mouse-derived allografts of gastric cancer.
- 2 June 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Combining Apatinib and Oxaliplatin Remodels the Immunosuppressive Tumor Microenvironment and Sensitizes Desert-Type Gastric Cancer to Immunotherapy
A transgenic mouse model and mouse-derived allografts of gastric cancer.